1,290,466 Celcuity, Inc. $CELC Shares Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Celcuity holdings by 685.9%, adding 1,290,466 shares to own 1.48 million shares, or 3.02% of the company, valued at approximately $117.6 million.
• Institutional investors and hedge funds collectively own 63.33% of Celcuity, with several other firms also raising or initiating positions during the recent quarters.
• Celcuity shares opened at $56.58, near the lower end of their 52-week range, after the company reported a quarterly EPS loss of $1.44 that missed estimates. Analysts maintain a “Moderate Buy” consensus, with an average price target of $154.25, despite some recent target cuts and a Zacks downgrade to “Strong Sell.”

Assenagon Asset Management S.A. boosted its holdings in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 685.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,478,607 shares of the company's stock after acquiring an additional 1,290,466 shares during the quarter. Assenagon Asset Management S.A. owned 3.02% of Celcuity worth $117,579,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CELC. PNC Financial Services Group Inc. grew its position in Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company's stock worth $59,000 after acquiring an additional 86 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Celcuity by 15.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company's stock worth $99,000 after acquiring an additional 124 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Celcuity by 1.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 31,092 shares of the company's stock valued at $3,253,000 after acquiring an additional 297 shares during the last quarter. Parallel Advisors LLC acquired a new position in shares of Celcuity during the 1st quarter valued at about $38,000. Finally, KBC Group NV bought a new position in shares of Celcuity in the 1st quarter valued at approximately $64,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Stock Down 6.2%

Shares of Celcuity stock opened at $56.58 on Friday. The company has a quick ratio of 8.93, a current ratio of 8.93 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 1-year low of $49.80 and a 1-year high of $151.02. The firm's 50-day moving average price is $82.95 and its two-hundred day moving average price is $99.80.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts expect that Celcuity, Inc. will post -4.82 EPS for the current year.

Analyst Upgrades and Downgrades

CELC has been the subject of several analyst reports. Zacks Research lowered Celcuity from a "hold" rating to a "strong sell" rating in a report on Tuesday. HC Wainwright reiterated a "buy" rating and set a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Needham & Company LLC lowered their price target on Celcuity from $140.00 to $134.00 and set a "buy" rating on the stock in a report on Wednesday, September 30th. Stifel Nicolaus reduced their price objective on shares of Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, August 14th. Finally, Citizens Jmp reaffirmed a "market outperform" rating and set a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Eleven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Celcuity has a consensus rating of "Moderate Buy" and a consensus price target of $154.25.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company's technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity's proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.